中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

The Combined Portfolio Diet and Exercise Study

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态招聘中
赞助商
St. Michael's Hospital, Toronto
合作者
Canadian Institutes of Health Research (CIHR)
University of Toronto
Laval University
University of Manitoba
University of British Columbia

关键词

抽象

The purpose of this study is to determine whether a dietary portfolio of cholesterol-lowering foods (viscous fibres, soy protein, plant sterols and nuts) further enhanced by increased levels of monounsaturated fatty acids (MUFA) and low glycemic index foods; together with a structured exercise program reduce the progression of carotid and coronary atheromatous lesions, Low density lipoprotein-cholesterol (LDL-C), and blood pressure, while reducing the number of individuals requiring statins.

描述

Presently in Canada, 29% of deaths are due to cardiovascular disease (CVD), costing $20.9 billion annually. The investigators have, therefore, brought together an unique network of investigators at different stages in their careers with a range of disciplines (nutrition, cardiology, diabetes, exercise physiology, imaging, physics, clinical trials, statistics, laboratory medicine, primary care, genetics, psychology, knowledge translation (KT), epidemiology), and with international recognition, experience and connections, to undertake a Canada-wide, multi-centre study which will test the ability of an effective cholesterol-lowering diet (dietary portfolio) and an exercise program, developed at Laval University, over 3 years to reduce the progression of plaque build-up in the carotid artery as assessed by Magnetic Resonance Imaging (MRI) in individuals with hypercholesterolemia and or type 2 diabetes. The dietary portfolio which has been proven in many of our studies to be an effective cholesterol-lowering diet will be enhanced to include features from other dietary strategies which the investigators have tested or developed; such as high monounsaturated fat (from Mediterranean diet) (CMAJ 2010) and low glycemic index foods (JAMA 2008). The investigators plan to recruit194 (approximately 200) men and postmenopausal women, who have measurable thickening (as assessed by ultrasound) due to plaque build up in the carotid arteries, in a 1.5 year period for this 3 year study. Ultrasound selection will be of individuals with intima-media thickness (IMT) >/=1.2mm as relevant arterial thickening to ensure a relatively low risk for the majority of the group, yet with some measurable arterial thickening.

Those selected will be randomly assigned to receive advice in one of four experimental arms: 1) Portfolio Plus diet and intensive increased physical activity program, 2) Portfolio Plus diet and a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity, 3) DASH-like diet and an intensive increased physical activity program and 4) DASH-like diet and a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity. The results of the study will have a major influence on dietary and exercise guidelines for coronary heart disease (CH risk reduction and provide evidence for the larger international trial that will focus on hard endpoints, myocardial infarction (MI) and CHD events). It is hoped that this cohort of participants will continue on and form part of the planned 9 year hard end point (MACE) study if funded.

Prior to starting treatments, participants will undergo screening ultrasound examination of both right and left carotids to enable selection of those individuals whose intima-media thickness (IMT) would be 5-30% below the cut point considered by the Mannheim Consensus as relevant arterial thickening to ensure a relatively low risk group, yet with some measurable arterial thickening.

It will be emphasized at the outset that both the dietary portfolio and the DASH-like diets have been associated with benefits in terms of cholesterol reduction to provide equal encouragement for all study arms. Portfolio and DASH-like dietary advice will consist of half hour individual sessions with the dietitian at baseline, and at 3-month intervals throughout the trial except for the first month when dietary advice will be reinforced, every 2 weeks, by telephone call to the participant or participant visit to the clinic. Prior to starting each diet, instruction will be given on achieving the dietary goals. At follow-up visits, the participants' completed 7-day diet records will be discussed and the original advice reinforced.

For the treatments with intensive increased physical activity the standardized physical activity/exercise component will be supervised by trained kinesiologists (exercise physiologists) for the 4 visits followed by monthly phone calls for the first year for the exercise component, when the major exercise training is provided. 7-day Exercise diaries will be collected at each visit. Using well-established procedures standardized across centers by the Quebec Heart and Lung Institute, the baseline visit will be used to provide a broad qualitative assessment of participants' lifestyle habits and preferences. Standardized physical activity questionnaires will be completed and participants will be asked to wear a pedometer for seven days prior to the intervention to quantify baseline physical activity (daily step count Cardiorespiratory fitness (CRF) is assessed using a submaximal treadmill test adapted from a progressive submaximal power output test performed on a cycle ergometer. The protocol begins with a warm-up workload of 2.5 mph with a 0% slope. The second stage is performed at a speed of 3.5 mph with a 2% slope. The third stage is adjusted in an attempt to reach 75% of the age-estimated maximal heart rate (HR). If necessary, a 4th stage is performed. Estimated VO2max is predicted by extrapolation to age-predicted maximal heart rate at a standardized submaximal treadmill stage (3.5 mph, 2% slope) and estimated maximal oxygen consumption (VO2max) are the variables considered as indicators of CRF in the present study.

For treatments with routine advice to increase physical activity, Health Canada Physical Activity Guidelines for adults 18-64 years or for older adults 65 years & older will be provided. They will be seen at the start and the end of each year for their formal exercise testing and will bring with them completed physical activities questionnaires. They will receive no other physical activities instruction.

Every effort will be made to obtain study blood samples and carotid imaging data from all subjects at the designated times regardless of adherence to the dietary aspects of the study protocol. All subjects will be included in the intention-to-treat analysis.

日期

最后验证: 09/30/2019
首次提交: 05/25/2015
提交的预估入学人数: 06/21/2015
首次发布: 06/24/2015
上次提交的更新: 10/07/2019
最近更新发布: 10/09/2019
实际学习开始日期: 11/24/2016
预计主要完成日期: 11/30/2020
预计完成日期: 11/30/2022

状况或疾病

Cardiovascular Diseases
Hypercholesterolemia
Type 2 Diabetes
Metabolic Syndrome

干预/治疗

Behavioral: Portfolio diet and structured exercise

Behavioral: DASH-like diet and structured exercise

Behavioral: Portfolio diet and routine exercise

Behavioral: DASH-like diet and routine exercise

-

手臂组

干预/治疗
Experimental: Portfolio diet and structured exercise
Participants will receive advice on a therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and be instructed on a standardized physical activity/exercise component supervised by kinesiologists.
Behavioral: Portfolio diet and structured exercise
Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale). Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily.
Active Comparator: DASH-like diet and structured exercise
Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and a be instructed on the Laval exercise program—a standardized physical activity/exercise component supervised by trained kinesiologists (exercise physiologists).
Behavioral: DASH-like diet and structured exercise
Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine. Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers.
Experimental: Portfolio diet and routine exercise
Participants will receive advice that will conform to the current therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
Behavioral: Portfolio diet and routine exercise
Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale). Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist.
Active Comparator: DASH-like diet and routine exercise
Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
Behavioral: DASH-like diet and routine exercise
Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine. Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist.

资格标准

有资格学习的年龄 21 Years 至 21 Years
有资格学习的性别All
接受健康志愿者
标准

A) Inclusion Criteria:

- Eligible participants will be

- men over 21 years

- post-menopausal women

Having a BMI less than or equal to 40 kg/m2 and who have measurable arterial thickening (>/=1.2mm) at screening as assessed by ultrasound.

They will include those who have at least 1 of the following characteristics:

1. Type 2 diabetes

2. Non-diabetic subjects post MI or post percutaneous coronary intervention (angioplasty) on statin therapy;

3. Hyper-cholesterolemic and treated with statins or have been prescribed statins but are not taking it because they are either unable (intolerant) or unwilling to take statin drugs.

4. Raised blood pressure, >140/90 (untreated)

B) Exclusion Criteria:

- Individuals with the following conditions will be excluded:

- cardiovascular disease that precludes exercise e.g.

- recent stroke or

- recent myocardial infarction or

- cardiac condition that severely compromises normal function:

- mitral valve disease, atrial fibrillation and individuals with Implantable Cardioverter Defibrillator (ICD)

- heart failure--grades 2-4 (based on New York Heart Association classification),

- severe angina sufficient to prevent any form of physical activity

- other conditions preventing exercise.

- secondary causes of hypercholesterolemia e.g. hypothyroidism (unless treated and on a stable dose of L-thyroxin), clinically significant renal (that precludes dietary change) or liver disease .

- LDL-cholesterol <1.4mmol/L

- uncontrolled blood pressure

- major disability

- disorder requiring continuous medical attention (on Coumadin) and treatment, such as:

- chronic heart failure

- liver disease

- renal failure or

- cancer (except non-melanoma skin cancer--basal cell, squamous cell)

- chronic infections (bacterial or viral)

- chronic inflammatory diseases (eg. lupus, ulcerative colitis, crohn's disease, celiac disease or gluten sensitivity)

- other autoimmune disease

- major surgery <6 months prior to randomization

- newly diagnosed with diabetes (<3 months)

- alcohol consumption >3 drinks/d

- not suitable for MRI examination because of metal implants or claustrophobia

- food allergies or sensitivity to study foods or study food components (eg. tree nuts, peanuts, soy, wheat, gluten, oats, eggs, milk)

- already following a portfolio-like diet (and are not prepared to change) or have a structured exercise program which they cannot increase any further

- do not have a family doctor

结果

主要结果指标

1. Change from baseline of the maximum vessel wall volume of the carotid arteries by MRI at year 1 and 3 [At months 0, 12 and 36]

MRI imaging assessment of the carotid arteries will be done at baseline, end of year 1 and year 3.

次要成果指标

1. Coronary atheroma in the large vessels by MRI at year 1 and 3 [At months 0, 12 and 36]

This will be assessed by MRI imaging of the Coronary and carotid arteries

2. Lipid rich necrotic core by MRI at year 1 and 3 [At months 0, 12 and 36]

This will be assessed by MRI imaging of the Coronary and carotid arteries

3. intra plaque hemorrhage by MRI at year 1 and 3 [At months 0, 12 and 36]

This will be assessed by MRI imaging of the Coronary and carotid arteries

4. Blood pressure and pulse rate [At months 0, 12 and 36]

This is a composite measure that would by done using an automatic digital BP monitor which simultaneously measures and displays systolic and diastolic pressure (mmHg) and pulse rate (bpm) readings on an output screen.

5. Treatment difference in initiation of statin therapy [At month 12 and 36]

Assessment will be based on the current Canadian Cardiovascular Society Guidelines

6. Composite endpoint of Myocardial Infarction, Revascularization, Cardio Vascular hospitalization, Cardiovascular mortality and stroke [at month 12 and 36]

Information will be obtained from medical records of participants affected

7. Atrial Fibrillation and heart failure [at month 12 and 36]

Information will be obtained from medical records of the participants

其他成果措施

1. Completeness of clinic attendance and data collection and provision of fasting blood samples for planned tests. [At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

This will be used as a measure of retention

2. Serum lipids: total cholesterol, LDL-chol, HDL-chol, and Triglycerides [At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

Serum lipids will be measured at each Centre on fasting serum. LDL-C will be calculated using the Friedewald equation. Serum lipid standards will be used to quality control the lipid analyses at the collaborating sites

3. Hemoglobin A1c [At months -3, -0.5, 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

safety monitoring especially for participants with type 2 diabetes

4. C-reactive protein [At months 0,12, 24 and 36]

C-reactive protein will be measured at each Centre on fasting serum.

5. Urinary analyses [At baseline (months -0.5 & 0) and end (months 33 & 36)]

24 hr urine samples will be analyzed for creatinine, urea, C-peptide, minerals, electrolytes and other dietary biomarkers

6. Fasting blood Glucose [At months -3, -0.5, 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

safety monitoring especially for participants with type 2 diabetes

7. Blood Pressure [At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

In clinic assessment using a digital blood pressure monitor

8. Treadmill testing [At month -1, and end of years 1, 2, and 3]

Physical fitness testing to assess fitness level

9. Diet history [At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

7-day food records brought in at 3 monthly intervals will be analysed for macro and micro nutrient intakes.

10. Exercise history [At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

7-day exercise/ activity records of the week prior to each study visit will be assessed for the type and duration of activity.

11. Pedometer records [At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

These will be assessed for the daily step count over a 7-day period prior to the specified time points for the test group only.

12. Survey on quality of life [At months 0 and 36.]

This will be done using a Medical Outcomes Study 36-Item Short Form Questionnaire (SF-36).

13. Palatability (taste) of diet [At months 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

This will be measure on a scale to 1 to 10. 1 being 'strongly dislike' and 10 being 'like very much'. Participants will rate the taste (palatability) of the study diet and dietary components.

14. Satiety [At months 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36]

Using a 9-point bipolar semantic scale where -4 is extremely hungry, 0 is neutral and +4 is uncomfortably full, participants will rate their overall feeling of satiety for the previous week

15. Sustainability of diet (preparedness to continue on the diet) [At months 33 and 36]

Participants' preparedness to continue on the diet will be measured on a scale of 1 to 10. 1 = diet not sustainable; 10 = diet very sustainable

16. Genetic testing for specific genes [Week 0 or any other time point]

One time sample collection of buffy coat (from white cells) for future study on gene, diet, exercise and chronic disease relationship

17. Complete blood count (CBC) [Months 0, 12, 24 and 36]

Health check at start and yearly intervals

18. Renal function tests [Months 0, 12, 24 and 36]

Health check at start and yearly intervals

19. Liver function tests [Months 0, 12, 24 and 36]

Health check at start and yearly intervals

20. Prostatic specific antigen (PSA) [Months 0, 12, 24 and 36]

Health check at start and yearly intervals for male participants

21. Cognitive Assessment [months 0, 12, 24 and 36]

The Montreal Cognitive Assessment (MoCA) (version 7.1 original version) will be administered at months 0, 12, 24 and 36. This tool measures different cognitive domains such as attention, concentration, memory, language etc.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge